Tamtam Try Tamtam free
Pfizer logo

Pfizer account plan

Developing innovative healthcare therapies

At a glance

Pfizer is a global biopharmaceutical company supplying about 200 countries: $62.6 billion FY2025 revenue and approximately 75,000 employees.

Pfizer Inc., headquartered in New York City, discovers, develops, manufactures and sells medicines and vaccines in oncology, internal medicine, vaccines, and inflammation and immunology, supplying approximately 200 countries and territories through 36 manufacturing plants. Products are sold mainly to wholesalers, with McKesson, Cencora and Cardinal Health taking 25%, 16% and 13% of 2025 revenues. FY2025 total revenues were $62.6 billion, down 2% as Paxlovid and Comirnaty fell, but up 6% operationally excluding those COVID-19 products; reported diluted EPS was $1.36 and adjusted diluted EPS $3.22. It had approximately 75,000 employees at December 31, 2025. Albert Bourla is Chairman and CEO.

Business units

Strategic priorities

Maximize key transactions
Extract value from Seagen (about $1 billion of cost synergies by end-2026), Metsera (about $600 million) and Biohaven; legacy Seagen U.S. sales grew 21% in Q2 2026.
Obesity
Develop berobenatide, the monthly GLP-1 from Metsera, with 10 Phase 3 studies planned in 2026 and a first approval targeted in 2028, in a market Pfizer sizes at $150 billion.
Post-2028 growth
Aim for a risk-adjusted high single-digit revenue CAGR from year-end 2028 through year-end 2033, built on in-line growth products and 20 key potential new medicines and vaccines.
Scale AI across the business
Use AI in R&D, manufacturing, commercial and patient engagement, including more than 1,200 GPUs, with the ambition of an AI-native R&D organization.
Cost savings
Total expected net savings are about $9.7 billion through 2029, including cost realignment of about $6.7 billion and manufacturing optimization of about $3.0 billion.

Latest results

In Q2 2026 (quarter to June 28, 2026) revenues rose 3% to $15,034 million, up 5% operationally excluding Comirnaty and Paxlovid, led by Eliquis ($2,425 million, +19% operationally), Padcev (+23%) and Lorbrena (+37%). The reported result was a loss of $(0.04) per diluted share after $4.3 billion of impairments, mainly $3.8 billion for sigvotatug vedotin after its Phase 3 lung-cancer readout; adjusted diluted EPS was $0.77. H1 2026 revenues were $29,484 million, up 4%. Pfizer raised 2026 revenue guidance to $60.5-62.5 billion, with COVID-19 revenue cut to about $4 billion, and reaffirmed adjusted EPS of $2.80-3.00.

Investments and deals

Metsera acquisition
Acquired on November 13, 2025 for $65.60 per share plus a CVR of up to $20.65 per share, for total consideration of $8.0 billion.
Innovent licensing deal
A deal for 12 early-stage ADC and multi-specific cancer programs, with $650 million upfront and up to $9.85 billion in milestones, closed July 10, 2026.
In-licensing from China
3SBio (oncology, including the PD-1xVEGF bispecific, a $1.35 billion charge) and YaoPharma (obesity, a $150 million charge) in 2025.
Divestments
The Haleon stake was sold for $6.3 billion in 2025 and the 11.7% ViiV stake exited for $1.875 billion on March 31, 2026.
Manufacturing and capex
About $2.5 billion of PP&E spending is expected in 2026; binding U.S. agreements on pricing and manufacturing investment set Pfizer's Section 232 tariff rate at zero until January 20, 2029.

Challenges and risks

Loss of exclusivity
A significant, accelerating revenue reduction is expected from 2026 through 2030, about $1.1 billion in 2026; Eliquis U.S. generics are permitted from April 1, 2028.
IRA price setting
The IRA Maximum Fair Price applies to Eliquis from January 1, 2026 and to Ibrance and Xtandi in 2027.
COVID-19 product decline
Paxlovid fell 95% and Comirnaty 34% in Q2 2026; 2026 COVID-19 revenue is now expected at about $4 billion.
Pipeline setbacks
Sigvotatug vedotin missed its Phase 3 overall-survival endpoint and Oxbryta was written down, driving $4.3 billion of Q2 2026 impairments.
Leverage and product concentration
Leverage was 2.7 times and is expected to stay there or modestly higher through the patent-expiry period; 12 products above $1 billion made 65% of 2025 revenues.

What leadership says

“clear line of sight to our aim of delivering a risk-adjusted high single-digit revenue CAGR from year-end 2028 through year-end 2033”

Albert Bourla, Chairman and CEO · Q2 2026 earnings call, August 4, 2026

“For the first time, we have shown that the GLP-1 receptor agonist peptides can be administered monthly”

Albert Bourla, Chairman and CEO · Q4 and full year 2025 earnings call, February 3, 2026

“We didn't just cut cost, what we did is we improved productivity”

Albert Bourla, Chairman and CEO · Q4 and full year 2025 earnings call, February 3, 2026

“our focus is maintaining our dividend at the moment and growing our dividend over time.”

David Denton, CFO · Q4 and full year 2025 earnings call, February 3, 2026

Where a supplier can help

AI for R&D and manufacturing
Tied to the scale-AI priority: AI infrastructure, data platforms and use cases in trial design, manufacturing yield and field-force targeting.
Clinical trial capacity for obesity
Tied to the obesity priority and 10 Phase 3 studies planned in 2026: CRO, patient recruitment and trial technology services.
Cost and productivity programs
Tied to the $9.7 billion savings target: automation and simplification in commercial, R&D and enabling functions.
U.S. manufacturing investment
Tied to the tariff agreement and manufacturing optimization: equipment, engineering and network restructuring services.
Launch commercialization
Tied to the loss-of-exclusivity challenge: omnichannel marketing and analytics that accelerate launched and acquired products such as Padcev and Nurtec.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Pfizer?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Pfizer

What does Pfizer do?

Pfizer is a research-based biopharmaceutical company that develops, manufactures and sells medicines and vaccines in oncology, internal medicine, vaccines, and inflammation and immunology in approximately 200 countries and territories.

What is Pfizer's revenue?

FY2025 total revenues were $62.6 billion, down 2%. 2026 guidance is $60.5-62.5 billion.

How many employees does Pfizer have?

Approximately 75,000 employees at December 31, 2025.

Who leads Pfizer?

Albert Bourla is Chairman and CEO. CFO David Denton is leaving and Cecile Guegan is interim CFO; Chris Boshoff is Chief Scientific Officer.

What is Pfizer's strategy?

Maximize the Seagen, Metsera and Biohaven deals, deliver R&D milestones especially in obesity and oncology, invest for growth after 2028 patent expiries, and scale AI while cutting about $9.7 billion of costs through 2029.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)